OBIO Orchestra BioMed Holdings, Inc. Insider Trading

David P Hochman purchased 5,000 shares of OBIO at $3.83; stock now down 27.9% from 52-week high as company burns cash amid growth.

David P Hochman purchased 5,000 shares at $3.83, increasing his total holdings to 1.06M shares, a modest 0.5% addition to his existing position. His cross-ticker track record shows weak timing discipline (21.43% 90-day win rate with average 90d return of +3.6%), and at OBIO specifically, he has mixed results: 3 of 5 prior buys posted positive 90-day returns, but his most recent purchase on 2026-05-15 has yielded only 1.6% gain at the 90-day mark. The company context raises concerns: OBIO is unprofitable with $-20.7M net income in its most recent full fiscal year, revenue of only $110.0K in the latest quarter, and the stock is currently -27.9% from its 52-week high. While the substantial annual revenue growth of +1169.2% appears dramatic, this reflects a very early-stage company with minimal absolute revenue, and the timing of this purchase against current price weakness and ongoing losses warrants scrutiny of whether the insider possesses non-public information or is simply averaging into a distressed position.

Director Aryeh Jason bought 8,971 shares of OBIO at $3.90 on 2026-05-15; prior buy at same ticker returned +77.1% in 90 days

Aryeh Jason, a Director at Orchestra BioMed Holdings (OBIO), purchased 8,971 shares at $3.90 on 2026-05-15 for $34,986.90, increasing his holdings by 8.3%. This buy mirrors a prior open-market purchase at OBIO on 2025-09-19, which delivered a +77.1% 90-day return. His cross-ticker buy history shows 1 prior buy with an avg 30d return of +35.5% and avg 90d return of +77.1%, with a 100.00% win rate on the 90-day mark. However, the stock is currently down -12.7% over the past 30 days and down -26.2% from its 52-week high of $5.42, suggesting the timing of this purchase relative to recent momentum warrants attention. The company remains unprofitable with net income of $-20.7M against revenue of $110.0K, though it recorded exceptional annual revenue growth of +1169.2%.

Hochman buys 5,000 OBIO shares at $3.77; stock -26.2% from 52-week high, -12.7% in 30 days

David P Hochman purchased 5,000 shares at $3.77 on 2026-05-15, expanding his holdings to 1.06M shares, while OBIO trades -26.2% below its 52-week high of $5.42 and -12.7% over the past 30 days. Among his prior trades at OBIO, timing results are mixed: 2 of 5 prior buys delivered positive 90-day returns, while the most recent buy on 2026-03-13 at an earlier price point returned -3.7% in 30 days and -7.2% over 90 days, suggesting recent buying has not been consistently rewarded. The company faces material headwinds—it reported $110.0K in latest quarterly revenue against a $-20.7M net loss for the most recent full year, though annual revenue growth of +1169.2% indicates recent acceleration from a very small base. The current purchase near depressed price levels warrants monitoring of whether the insider perceives stabilization or whether further deterioration follows.

Director Fain Eric S bought 20,000 shares of OBIO at $4.13 on 2026-05-14; holding reaches 91.7K shares. Stock at $4.00, down -26.2% from 52-week high.

Director Fain Eric S purchased 20,000 shares at $4.13, increasing his stake from 71.7K to 91.7K shares (+27.9%). The transaction occurs with the stock trading at $4.00, substantially below its 52-week high of $5.42 and down -12.7% over the prior 30 days. His prior buy at this ticker on 2025-08-25 showed a 90-day return of +73.6%, which was well-timed. Additionally, 2 other insiders bought within the past 14 days, creating a cluster pattern of insider purchases. The company reported revenue of $110.0K in its latest quarter but net income of $-20.7M, with negative full-year profitability, setting this accumulation against a financially distressed backdrop.